| ABT |
Abbott Laboratories |
72%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from SVA graph: bined with greater affordability relative to comparable products offered by multinational competitors. Our ability to s… |
| ABT |
Abbott Laboratories |
72%
|
bined with greater affordability relative to comparable products offered by multinational competitors. Our ability to sustain this positioning also depends on our capacity to adapt promptly to China'… |
| IAALF |
IAALF |
72%
|
on our assessment of the collectability of specific customer accounts and the aging of the accounts receivable. We analyze accounts receivable and historical bad debts, customer concentrations, custo… |
| IAALF |
IAALF |
72%
|
Reciprocal relationship from IAALF graph: Reciprocal relationship from SVA graph: on our assessment of the collectability of specific customer accounts and the aging of the accounts receivable. We an… |
| PCCYF |
PetroChina Company Limited |
72%
|
Reciprocal relationship from PCCYF graph: Reciprocal relationship from SVA graph: on our assessment of the collectability of specific customer accounts and the aging of the accounts receivable. We an… |
| PCCYF |
PetroChina Company Limited |
72%
|
on our assessment of the collectability of specific customer accounts and the aging of the accounts receivable. We analyze accounts receivable and historical bad debts, customer concentrations, custo… |
| SBMFF |
SBMFF |
72%
|
livelihood and major public interests, shall be subject to stricter management system. In addition, we may need to comply with increasingly complex and rigorous regulatory standards enacted to protec… |
| SBMFF |
SBMFF |
72%
|
Reciprocal relationship from SBMFF graph: Reciprocal relationship from SVA graph: Reciprocal relationship from SBMFF graph: Reciprocal relationship from SVA graph: livelihood and major public interes… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from SVA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from SVA graph: Reciprocal relationship from SNYNF … |
| SNYNF |
Sanofi |
72%
|
bined with greater affordability relative to comparable products offered by multinational competitors. Our ability to sustain this positioning also depends on our capacity to adapt promptly to China'… |
| VXRT |
Vaxart, Inc. |
72%
|
Reciprocal relationship from VXRT graph: Reciprocal relationship from SVA graph: Reciprocal relationship from VXRT graph: Reciprocal relationship from SVA graph: Reciprocal relationship from VXRT gra… |
| BEIJING-KUAI-LE-XING-BIOTECH-CO-LTD |
BEIJING-KUAI-LE-XING-BIOTECH-CO-LTD |
62%
|
livelihood and major public interests, shall be subject to stricter management system. In addition, we may need to comply with increasingly complex and rigorous regulatory standards enacted to protec… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
SEC related to its offer to purchase for cash, subject to the terms and conditions set forth in the offer to purchase, up to a maximum of 10,000,000 shares of Sinovac Antigua at a purchase price of $… |
| CGEN |
Compugen Ltd. |
62%
|
Reciprocal relationship from CGEN graph: Reciprocal relationship from SVA graph: Reciprocal relationship from CGEN graph: Reciprocal relationship from SVA graph: Reciprocal relationship from CGEN gra… |
| CHANGCHUN-BCHT-BIOTECHNOLOGY-CO-LTD |
CHANGCHUN-BCHT-BIOTECHNOLOGY-CO-LTD |
62%
|
artment of Health and Human Services. NIH has granted us a non-exclusive license to import and use certain Rotavirus Strains and Monoclonal Antibodies ("Biological Materials") to develop an oral rota… |
| CHANGCHUN-CHANGSHENG-LIFE-SCIENCE-CO-LTD |
CHANGCHUN-CHANGSHENG-LIFE-SCIENCE-CO-LTD |
62%
|
uisition of new production lines, technologies, businesses, products or services or the creation of strategic alliances in areas in which we do not currently operate. These acquisitions and strategic… |
| CHINA-NATIONAL-BIOTEC-GROUP |
CHINA-NATIONAL-BIOTEC-GROUP |
62%
|
artment of Health and Human Services. NIH has granted us a non-exclusive license to import and use certain Rotavirus Strains and Monoclonal Antibodies ("Biological Materials") to develop an oral rota… |
| CNBG-WALVAX-BIOTECHNOLOGY-CO-LTD |
CNBG-WALVAX-BIOTECHNOLOGY-CO-LTD |
62%
|
artment of Health and Human Services. NIH has granted us a non-exclusive license to import and use certain Rotavirus Strains and Monoclonal Antibodies ("Biological Materials") to develop an oral rota… |
| COGENCY-GLOBAL-INC |
COGENCY-GLOBAL-INC |
62%
|
livelihood and major public interests, shall be subject to stricter management system. In addition, we may need to comply with increasingly complex and rigorous regulatory standards enacted to protec… |
| DALIAN-JIN-GANG-GROUP |
DALIAN-JIN-GANG-GROUP |
62%
|
, and also have provided counter guarantees to Sinovac Life Science proportionately with respect to its loan guarantee. On April 24, 2026, the Company approved Sinovac Hong Kong to provide a loan of … |
| HUALAN-VACCINE-INC |
HUALAN-VACCINE-INC |
62%
|
artment of Health and Human Services. NIH has granted us a non-exclusive license to import and use certain Rotavirus Strains and Monoclonal Antibodies ("Biological Materials") to develop an oral rota… |
| NET-FORCE-SYSTEM-INC |
NET-FORCE-SYSTEM-INC |
62%
|
livelihood and major public interests, shall be subject to stricter management system. In addition, we may need to comply with increasingly complex and rigorous regulatory standards enacted to protec… |
| OVERSEAS-PUBLICLY-LISTED-COMPANY |
OVERSEAS-PUBLICLY-LISTED-COMPANY |
62%
|
livelihood and major public interests, shall be subject to stricter management system. In addition, we may need to comply with increasingly complex and rigorous regulatory standards enacted to protec… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
uisition of new production lines, technologies, businesses, products or services or the creation of strategic alliances in areas in which we do not currently operate. These acquisitions and strategic… |
| PUKANG-BIOLOGICAL-CO-LTD |
PUKANG-BIOLOGICAL-CO-LTD |
62%
|
artment of Health and Human Services. NIH has granted us a non-exclusive license to import and use certain Rotavirus Strains and Monoclonal Antibodies ("Biological Materials") to develop an oral rota… |
| SHAREHOLDER-GROUP |
SHAREHOLDER-GROUP |
62%
|
3 - $ 200 , 2022 - $ 206 , 2021 - $ 223 ). During the years ended December 31, 2024, 2023, 2022 and 2021, changes in the Company's current deferred revenue were as follows: Balance, Beginning of Peri… |
| SINOBIOWAY-BIO-MEDICINE-CO-LTD |
SINOBIOWAY-BIO-MEDICINE-CO-LTD |
62%
|
r vaccine research and development technology platform. If we do not spend our development budget efficiently or effectively on innovative and commercially successful technologies, we may not realize… |
| U-S-INVESTMENT-COMPANY |
U-S-INVESTMENT-COMPANY |
62%
|
uisition of new production lines, technologies, businesses, products or services or the creation of strategic alliances in areas in which we do not currently operate. These acquisitions and strategic… |
| XIAMEN-BIOWAY-GROUP-CO-LTD |
XIAMEN-BIOWAY-GROUP-CO-LTD |
62%
|
r vaccine research and development technology platform. If we do not spend our development budget efficiently or effectively on innovative and commercially successful technologies, we may not realize… |
